DOSSIER · 13F-HR · Q3 2026

BAKER BROS. ADVISORS LP

$21.0B in tracked AUM across 80 positions as of Q3 2026.

BB
CIK 0001263508 · last filed Sep 30, 2026
Total AUM
$21.0B
as of Q3 2026
Holdings
80
−6 QoQ
positions
Whale Score
82
82
strong
Activity
78
+18 new, −24 sold
changes this Q
AI Analysis · Q3 2026

BAKER BROS. ADVISORS LP filed its latest 13F-HR for Q3 2026. 78 position changes this quarter — 18 new, 24 exited, 23 added, 13 trimmed.

Quarter at a glance — Q3 2026

78 material changes this filing.

ADD
KODKodiak Sciences Inc.
+1.9M sh
+$1.5B
9.8%
ADD
RVMDRevolution Medicines, Inc.
+1.2M sh
+$1.4B
10.4%
ADD
INCYIncyte Corporation
+19K sh
+$696M
17.7%
ADD
ONCBeOne Medicines Ltd.
+33K sh
+$559M
15.4%
TRIM
CELCCelcuity Inc.
-3.1M sh
$-407M
1.8%
ADD
ABCLAbCellera Biologics Inc.
+5.5M sh
+$388M
2.3%
ADD
GRALGRAIL, Inc.
+1.9M sh
+$386M
2.7%

Top 10 holdings

By portfolio weight as of Q3 2026. Source: SEC EDGAR 13F-HR filings.

#HoldingValueSharesWeight
01
INCY
Incyte Corporation
$3.7B30.8M17.7%
02
ONC
BeOne Medicines Ltd.
$3.2B8.8M15.4%
03
RVMD
Revolution Medicines, Inc.
$2.2B10.6M10.4%
04
KOD
Kodiak Sciences Inc.
$2.1B21.9M9.8%
05
MDGL
Madrigal Pharmaceuticals, Inc.
$1.1B2.1M5.1%
06
INSM
Insmed Incorporated
$1.0B8.8M4.8%
07
KYMR
Kymera Therapeutics, Inc.
$968M8.7M4.6%
08
ACAD
ACADIA Pharmaceuticals Inc.
$865M42.9M4.1%
09
GRAL
GRAIL, Inc.
$564M4.0M2.7%
10
SMMT
Summit Therapeutics Inc.
$554M32.8M2.6%

Filing history

2026Q3Sep 30
$21.0B▲ 23.2%
80 positionsView →
2025Q4Dec 31
$17.1B▲ 67.8%
86 positionsView →
2025Q3Sep 30
$10.2B▼ 1.3%
67 positionsLocked
2025Q2Jun 30
$10.3B▲ 14.1%
89 positionsLocked
2025Q1Mar 31
$9.0B▼ 3.5%
89 positionsLocked
2024Q4Dec 31
$9.4B▼ 3.0%
95 positionsLocked
2024Q3Sep 30
$9.6B▲ 23.3%
93 positionsLocked
2024Q2Jun 30
$7.8B▼ 1.8%
95 positionsLocked
2024Q1Mar 31
$8.0B▼ 9.3%
87 positionsLocked
2023Q4Dec 31
$8.8B▼ 49.3%
84 positionsLocked
2023Q3Sep 30
$17.4B▲ 0.4%
101 positionsLocked
2023Q2Jun 30
$17.3B▼ 6.0%
107 positionsLocked
Showing 12 of 94